NasdaqGS:BBIOBiotechs
BridgeBio (BBIO) Stock Still Looks Pricey After FDA Filing Acceptance
BridgeBio Pharma stock has delivered a 149.6% return over the past three years, yet its valuation checks lean expensive and suggest the recent strength may already price in a lot of good news. With the company now highlighting a potential blockbuster opportunity around its encaleret program, investors are weighing strong share price gains against a weaker value score.
BridgeBio Pharma has returned 149.6% over three years, which puts extra focus on whether the current share price still offers...